TY - JOUR
T1 - Philadelphia-Negative Myeloproliferative Neoplasms
T2 - Laboratory Workup in the Era of Next-Generation Sequencing
AU - Zuo, Zhuang
AU - Li, Shaoying
AU - Xu, Jie
AU - You, M. James
AU - Khoury, Joseph D.
AU - Yin, C. Cameron
N1 - Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Purpose of Review: To review the impact of next-generation sequencing (NGS) on laboratory approach of myeloproliferative neoplasms (MPNs). Recent Findings: Next-generation sequencing has provided valuable information on the mutational landscape of MPNs and has been used for various applications, including diagnosis, risk stratification, monitoring of residual disease or disease progression, and target therapy. Most commonly, targeted sequencing of a panel of genes that have been shown to be recurrently mutated in myeloid neoplasms is used. Although numerous studies have shown the benefit of using NGS in the routine clinical care of MPN patients, the complexity of NGS data and how these data may contribute to the clinical outcome have limited the development of a standard clinical guideline. Summary: We review recent literature and discuss how to interpret and use NGS data in the clinical care of MPN patients.
AB - Purpose of Review: To review the impact of next-generation sequencing (NGS) on laboratory approach of myeloproliferative neoplasms (MPNs). Recent Findings: Next-generation sequencing has provided valuable information on the mutational landscape of MPNs and has been used for various applications, including diagnosis, risk stratification, monitoring of residual disease or disease progression, and target therapy. Most commonly, targeted sequencing of a panel of genes that have been shown to be recurrently mutated in myeloid neoplasms is used. Although numerous studies have shown the benefit of using NGS in the routine clinical care of MPN patients, the complexity of NGS data and how these data may contribute to the clinical outcome have limited the development of a standard clinical guideline. Summary: We review recent literature and discuss how to interpret and use NGS data in the clinical care of MPN patients.
KW - Chronic neutrophilic leukemia
KW - Essential thrombocythemia
KW - Myeloproliferative neoplasms
KW - Next-generation sequencing
KW - Polycythemia vera
KW - Primary myelofibrosis
UR - http://www.scopus.com/inward/record.url?scp=85070284291&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070284291&partnerID=8YFLogxK
U2 - 10.1007/s11899-019-00534-8
DO - 10.1007/s11899-019-00534-8
M3 - Review article
C2 - 31388824
AN - SCOPUS:85070284291
SN - 1558-8211
VL - 14
SP - 376
EP - 385
JO - Current hematologic malignancy reports
JF - Current hematologic malignancy reports
IS - 5
ER -